Ani Pharmaceuticals Inc (ANIP) Institutional Ownership

Ownership Summary

Ani Pharmaceuticals Inc (NASDAQ:ANIP) appears in 276 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 99.6% of Ani Pharmaceuticals's outstanding shares in December 2025, up from 98.2% in September 2025.
• Their total shares held in ANIP increased 7.06% from the prior quarter, while the number of investors in Ani Pharmaceuticals increased 35.96% year over year.
• Among the 276 funds, 160 bought more Ani Pharmaceuticals shares, 75 sold down, and 41 held their ground.
• In total, institutional investors held 21.0Mn shares in Ani Pharmaceuticals as of December 2025, up by 1.39Mn shares quarter on quarter, and up 1.04Mn shares year over year.
• As of December 31, 2025, BlackRock, Inc. held the largest stake in Ani Pharmaceuticals with 2.75Mn shares, accounting for 13.03% of total shares outstanding.
• The most significant purchases of ANIP for the quarter ending December 2025 came from VANGUARD CAPITAL MANAGEMENT LLC (823.06K), GOLDENTREE ASSET MANAGEMENT LP (667.98K), VANGUARD PORTFOLIO MANAGEMENT LLC (375.96K), UBS Group AG (346.92K), Soleus Capital Management, L.P. (334.0K).
• Leading sellers of Ani Pharmaceuticals shares for the quarter ending December 2025 were Goldman Sachs Group Inc (580.8K), Global Alpha Capital Management Ltd. (228.9K), BNP PARIBAS FINANCIAL MARKETS (129.93K), RENAISSANCE TECHNOLOGIES LLC (128.3K), TWO SIGMA INVESTMENTS, LP (84.34K).
• Business Quant data shows the 10 biggest positions in Ani Pharmaceuticals as of December 2025 are held by BlackRock, Inc. (2.75Mn), VANGUARD CAPITAL MANAGEMENT LLC (823.06K), Soleus Capital Management, L.P. (820.24K), State Street Corp (771.59K), TANG CAPITAL MANAGEMENT LLC (707.5K), GOLDENTREE ASSET MANAGEMENT LP (667.98K), Deep Track Capital, LP (600.0K), MILLENNIUM MANAGEMENT LLC (592.01K), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (564.36K), DIMENSIONAL FUND ADVISORS LP (531.19K).